



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Eva-Maria PRINZENBERG et al.

Art Unit:

1634

Application No.: 10/524,295

Examiner:

Bausch, S.

Filed: September 29, 2005

Attorney Dkt. No.: 12007-0047

For: METHOD FOR SCREENING THE ALLELIC STATE AT THE 5'-FLANKING REGION

OF THE aS1 CASEIN GENE (as amended)

RESPONSE TO COMMUNICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In the Office Communication of July 17, 2008, the Examiner indicated that the sequence listing rules have not fully been complied with since Figures 1 and 2 identified sequence listings, but no identifier was shown as part of the drawings.

In order to comply with the sequence listing rules, a Letter to the Draftsperson is submitted with corrected Figures 1 and 2. In Figure 1, the sequence listing identifier of SEQ NO ID: 3 is shown with SEQ NO ID: 5 shown for Figure 2. It is submitted that all of the sequence listings shown in the drawings and specification have been properly identified so that an examination on the merits of this application can proceed.

The Examiner is invited to contact the undersigned if other issues arise.

Application No.: 10/524,295

Applicants respectfully submit that there is no fee required for this submission, however, please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,

CLARK & BRODY

Christopher W. Brody

Registration No. 33,613

Customer No. 22902

1090 Vermont Avenue, NW, Suite 250

Washington, DC 20005 Telephone: 202-835-1111 Facsimile: 202-835-1755

Docket No.: 12007-0047 Date: August 15, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Eva-Maria PRINZENBERG et al.

Art Unit:

1634

Application No.: 10/524,295

Examiner:

Bausch, S.

Filed: September 29, 2005

Attorney Dkt. No.: 12007-0047

For: METHOD FOR SCREENING THE ALLELIC STATE AT THE 5'-FLANKING REGION

OF THE aS1 CASEIN GENE (as amended)

LETTER TO DRAFTSPERSON

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Communication of July 17, 2008, submitted herewith are corrected Figures 1 and 2, each showing the sequence listing identifier corresponding to the illustrated sequence listing.

Applicants respectfully submit that there is no fee required for this submission, however, please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,

CLARK & BRODY

Christopher W. Brody

Registration No. 33,613

Customer No. 22902

1090 Vermont Avenue, NW, Suite 250

Washington, DC 20005 Telephone: 202-835-1111 Facsimile: 202-835-1755

Docket No.: 12007-0047 Date: August 15, 2008





United

Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,295	09/29/2005	Eva-Maria Prinzenberg	12007-0047	5679
22902 CLARK & BR	7590 07/17/2008 ODY		EXAM	INER
1090 VERMONT AVENUE, NW			BAUSC	SARAE L
SUITE 250 WASHINGTO	N, DC 20005		ART UNIT PAPER NUMBE	
	•		1634	
				- · · · ·
			MAIL DATE	DELIVERY MODE
	•		07/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.





UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.J CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10524295	9/29/05	PRINZENBERG ET AL.	12007-0047

CLARK & BRODY 1090 VERMONT AVENUE, NW SUITE 250 WASHINGTON, DC 20005 SARAE BAUSCH

ART UNIT PAPER

1634 20080715

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

As indicated in the restriction mailed 03/20/2008, Applicant was required to comply will sequence rules. The specification contains sequences that do not comply with the sequence rules. Figures 1 and figures 2 contain sequences that are more than ten nucleotides and these sequences do not have sequence identifiers. Applicant should review the entire application and fully comply with all sequence rules.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/Sarae Bausch/ Primary Examiner Art Unit: 1634